Cannabidiol dose dependently reduces alcohol intake in mice via a non‐5‐HT 1A receptor mechanism: Exploration of other potential receptor targets
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70070 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Connie J Badolato and 4 co-authors. Institution: Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia. Major MEDLINE topics: Cannabidiol, Receptor, Serotonin, 5-HT1A, Alcohol Drinking. Cited 2 times so far (Crossref); 89 references. The full text is freely available (open access, CC BY 4.0). Funded by: Lambert Family to The University of Sydney, Australian National Health and Medical Research Council.
Abstract (original language)
Background and Purpose Binge drinking is a risky pattern of alcohol intake and a major predictor of alcohol use disorder (AUD). Current AUD medications have limited efficacy and poor patient compliance, calling for more effective therapeutics. Cannabidiol (CBD), a non‐intoxicating component of cannabis, has emerged as a potential novel therapeutic. However, receptor mechanisms in CBD's alcohol‐related effects have not been investigated comprehensively. Experimental Approach Using the murine drinking‐in‐the‐dark model of binge drinking, our research aimed to confirm a reduction of alcohol consumption with CBD (7.5, 15, 30, 60, 120 mg kg −1 ) in male and female mice. Behavioural pharmacological approaches were used to explore CBD interactions with identified target mechanisms: serotonin‐1A receptor (5‐HT 1A R) and peroxisome proliferator‐activated receptor‐gamma (PPARɣ), and the novel targets, chemokine receptor type‐4 (CXCR4) and neuropeptide S receptor (NPSR). Key Results Acute CBD dose dependently suppressed binge‐like drinking and blood ethanol concentration. The effect was not driven by locomotor impairments and was maintained across sub‐chronic treatment. Blockade of 5‐HT 1A R and PPARɣ had no impact on CBD's reduction of alcohol consumption. Co‐administration of subthreshold CBD doses and a NPSR antagonist implicated NPSR blockade as a potential mechanism contributing to CBD's effect, whereas co‐administration of CBD and a CXCR4 antagonist suggested CXCR4 was not involved. However, the potent and selective CXCR4 antagonist AMD3100 reduced ethanol consumption. Conclusions and Implications CBD represents a promising candidate to reduce voluntary alcohol consumption. Mechanisms driving CBD's alcohol‐related effects remain unclear and may involve polypharmacology, including actions at the NPSR identified in the present study.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.
- Faculty of Science, School of Psychology, The University of Sydney, Camperdown, New South Wales, Australia.
- Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Camperdown, New South Wales, Australia.
- Faculty of Medicine and Health, Sydney Pharmacy School, The University of Sydney, Camperdown, New South Wales, Australia.
ORCID profiles: Connie J Badolato
Funding
- Lambert Family to The University of Sydney
- Australian National Health and Medical Research Council
Cite
APA
Badolato, C. J., Lynch, E. A., Arnold, J. C., McGregor, I. S., & Bowen, M. T. (2025). Cannabidiol dose dependently reduces alcohol intake in mice via a non‐5‐HT 1A receptor mechanism: Exploration of other potential receptor targets. British Journal of Pharmacology. https://doi.org/10.1111/bph.70070
Vancouver
Badolato CJ, Lynch EA, Arnold JC, McGregor IS, Bowen MT. Cannabidiol dose dependently reduces alcohol intake in mice via a non‐5‐HT 1A receptor mechanism: Exploration of other potential receptor targets. British Journal of Pharmacology. 2025. doi:10.1111/bph.70070
BibTeX
@article{Badolato2025,
author = {Badolato, Connie J and Lynch, Erin A and Arnold, Jonathon C and McGregor, Iain S and Bowen, Michael T},
title = {Cannabidiol dose dependently reduces alcohol intake in mice via a non‐5‐HT 1A receptor mechanism: Exploration of other potential receptor targets},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70070}
}
EUVIMED